Bicara Therapeutics (NASDAQ:BCAX) and Compass Therapeutics (NASDAQ:CMPX) Head to Head Review

Compass Therapeutics (NASDAQ:CMPX) and Bicara Therapeutics (NASDAQ:BCAX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Compass Therapeutics and Bicara Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Compass Therapeutics	1	0	12	1	2.93
Bicara Therapeutics	1	3	8	0	2.58

Compass Therapeutics presently has a consensus target price of $14.20, suggesting a potential upside of 142.74%. Bicara Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 18.04%. Given Compass Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe Compass Therapeutics is more favorable than Bicara Therapeutics.

Insider & Institutional Ownership

68.4% of Compass Therapeutics shares are owned by institutional investors. 29.8% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Compass Therapeutics and Bicara Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Compass Therapeutics	N/A	-43.61%	-38.05%
Bicara Therapeutics	N/A	-32.49%	-30.87%

Earnings & Valuation

This table compares Compass Therapeutics and Bicara Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Compass Therapeutics	$850,000.00	1,239.44	-$66.49 million	($0.43)	-13.60
Bicara Therapeutics	N/A	N/A	-$137.95 million	($2.53)	-9.38

Compass Therapeutics has higher revenue and earnings than Bicara Therapeutics. Compass Therapeutics is trading at a lower price-to-earnings ratio than Bicara Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Compass Therapeutics has a beta of 1.49, indicating that its share price is 49% more volatile than the S&P 500. Comparatively, Bicara Therapeutics has a beta of -1.23, indicating that its share price is 223% less volatile than the S&P 500.

Summary

Compass Therapeutics beats Bicara Therapeutics on 10 of the 13 factors compared between the two stocks.

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

About Bicara Therapeutics

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.